Correlation of efficacy between EGFR gene copy number and lapatinib/capecitabine therapy in HER2-positive metastatic breast cancer.
Alessandra Fabi(Agostino Gemelli University Polyclinic), Francesco Cognetti(Apple (Israel)), Marcella Mottolese, Giulio Metro(University of Perugia), Roberta Merola, G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Isabella Sperduti(San Gallicano Hospital), A. Di Benedetto, Paola Papaldo(Cancer Institute (WIA)), Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 2
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
|JAMA Oncology|2018|345
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma
|Journal of Clinical Oncology|2020|226